Idecabtagene Vicleucel Infusion Suppliers & Bulk Manufacturers

Available Forms: IV Infusion

Available Strengths: Approved for relapsed/refractory multiple myeloma, with dosing based on patient weight, delivering a personalized, targeted therapy to eliminate cancer cells

Reference Brands: Abecma(US & EU)

Category: Cell & Gene Therapies

Idecabtagene vicleucel, an autologous BCMA-directed CAR-T cell infusion for relapsed and refractory multiple myeloma, made for each patient. For qualified treatment centres working with the authorisation holder.

Product Description:

Idecabtagene vicleucel is an autologous CAR-T cell therapy. A patient's own T cells are collected by leukapheresis, modified with a lentiviral vector to carry a chimeric antigen receptor against B-cell maturation antigen (BCMA), expanded and returned as a single intravenous infusion. BCMA sits on myeloma cells, so the engineered cells seek them out and kill them. The dose is a range of CAR-positive viable T cells stated on the batch certificate, not a milligram strength, and it is not calculated per kilogram.

It is used for adults with relapsed and refractory multiple myeloma already treated with an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody. Patients first receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide. Cytokine release syndrome and neurological toxicity are frequent and can be severe, so tocilizumab must be on site before infusion and patients stay near the centre for several weeks. Prolonged low blood counts, infections, haemophagocytic lymphohistiocytosis and secondary blood cancers, including T-cell malignancies, are labelled risks.

Sourcing notes. This therapy cannot be bought as stock. Supply runs only through the authorisation holder's controlled network to qualified, trained treatment centres, or through named-patient routes where national law allows, with apheresis, manufacture and infusion linked by a strict chain of identity. The cells travel cryopreserved in the vapour phase of liquid nitrogen and are thawed at the bedside. A hospital planning to offer it should clarify centre qualification, staff training, import rules for advanced therapy and genetically modified products, and pharmacovigilance duties. Refuse any offer from outside that network.